Hepatitis C‐Associated Focal Proliferative Glomerulonephritis in an Aviremic Recipient of a Hepatitis C Positive Antibody Donor Liver

2021 ◽  
Author(s):  
Humberto Bohorquez ◽  
Juan Carlos Q. Velez ◽  
Mark Lusco ◽  
Jennifer Scheuermann ◽  
Ari J Cohen
Keyword(s):  
Hepatitis C ◽  
Proliferative Glomerulonephritis ◽  
Donor Liver ◽  
Positive Antibody ◽  
Focal Proliferative Glomerulonephritis

scholarly journals Hepatitis C disease severity in living versus deceased donor liver transplant recipients: An extended observation study

Hepatology ◽  
2014 ◽  
Vol 59 (4) ◽  
pp. 1311-1319 ◽  
Author(s):  
Norah A. Terrault ◽  
R. Todd Stravitz ◽  
Anna S.F. Lok ◽  
Greg T. Everson ◽  
Robert S. Brown ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Transplant ◽  
Disease Severity ◽  
Deceased Donor ◽  
Transplant Recipients ◽  
Donor Liver ◽  
Observation Study ◽  
Donor Liver Transplant ◽  
Liver Transplant Recipients

Anämie, Thrombozytopenie und Fieber bei HIV-Infektion

Praxis ◽  
2003 ◽  
Vol 92 (9) ◽  
pp. 406-408
Author(s):  
Strub
Keyword(s):  
Hepatitis C ◽  
Proliferative Glomerulonephritis ◽  
Sich Eine ◽  
Wird Eine ◽  
Thrombotische Mikroangiopathie ◽  
Seltene Erkrankung

Die 40-jährige Patientin stellt sich wegen neu aufgetretenen Unterschenkel- und Gesichtsödemen vor. Sie ist bereits seit Jahren wegen einer therapiebedürftigen HIV-Infektion bekannt, die antiretroviralen Medikamente nimmt sie jedoch unregelmässig ein. Im Blutbild finden sich eine deutliche Anämie und Thrombozytopenie. Wegen einer massiven Proteinurie wird eine Nierenbiopsie durchgeführt. Es zeigt sich eine thrombotische Mikroangiopathie und eine wahrscheinlich Hepatitis C-assoziierte proliferative Glomerulonephritis. Die thrombotische Mikroangiopathie ist eine seltene Erkrankung und kann alle Organe befallen, wobei es immer zu einer hämolytischen Anämie und einer Thrombozytopenie kommt, meist auch zu Fieber. Die Krankheitsinzidenz scheint durch die HIV-Infektion erhöht zu sein und die Prognose ist insbesondere bei fortgeschrittener AIDS-Erkrankung trotz Plasmapherese schlecht.

scholarly journals PNPLA3 as a liver steatosis risk factor following living-donor liver transplantation for hepatitis C

2017 ◽  
Vol 48 (3) ◽  
pp. E335-E339 ◽  
Author(s):  
Hisamitsu Miyaaki ◽  
Satoshi Miuma ◽  
Naota Taura ◽  
Hidetaka Shibata ◽  
Akihiko Soyama ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Risk Factor ◽  
Hepatitis C ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Liver Steatosis ◽  
Donor Liver ◽  
Donor Liver Transplantation

scholarly journals Living-Donor Liver Transplantation and Hepatitis C

HPB Surgery ◽  
2013 ◽  
Vol 2013 ◽  
pp. 1-13 ◽  
Author(s):  
Nobuhisa Akamatsu ◽  
Yasuhiko Sugawara
Keyword(s):  
Liver Transplantation ◽  
Hepatitis C ◽  
Living Donor ◽  
Living Donor Liver Transplantation ◽  
Antiviral Treatment ◽  
Sustained Viral Response ◽  
Deceased Donor ◽  
Donor Liver ◽  
Donor Liver Transplantation ◽  
Primary Indication

Hepatitis-C-virus- (HCV-) related end-stage cirrhosis is the primary indication for liver transplantation in many countries. Unfortunately, however, HCV is not eliminated by transplantation and graft reinfection is universal, resulting in fibrosis, cirrhosis, and finally graft decompression. In areas with low deceased-donor organ availability like Japan, living-donor liver transplantation (LDLT) is similarly indicated for HCV cirrhosis as deceased-donor liver transplantation (DDLT) in Western countries and accepted as an established treatment for HCV-cirrhosis, and the results are equivalent to those of DDLT. To prevent graft failure due to recurrent hepatitis C, antiviral treatment with pegylated-interferon and ribavirin is currently considered the most promising regimen with a sustained viral response rate of around 30% to 35%, although the survival benefit of this regimen remains to be investigated. In contrast to DDLT, many Japanese LDLT centers have reported modified treatment regimens as best efforts to secure first graft, such as aggressive preemptive antiviral treatment, escalation of dosages, and elongation of treatment duration.

Sign in / Sign up

Export Citation Format

Share Document